Myant Corp. has purchased mmHg Inc., a digital health company specializing in remote blood pressure monitoring, cardiovascular risk reduction, and chronic disease management. The deal is part of a broader strategy of “prevention through precision” to drive forward a new era of personalized, artificial intelligence (AI)-enabled remote healthcare.

Neither company disclosed the transaction’s terms.

This acquisition expands Myant’s geographic footprint and market reach to the United States, where mmHg has a significant existing customer base, including a partnership with one of the largest manufacturers of highly accurate, reliable medical devices and health products—A&D Medical.

“Our company is on a mission to make healthy aging a reality for millions. We want to turn the tide on chronic conditions and redefine what it means to grow older. This acquisition enhances our ability to offer comprehensive cardiovascular monitoring and risk management solutions, strengthening our role in transforming digital health and enabling this large ageing demographic to live younger, longer,” Myant CEO Tony Chahine said.

mmHg’s platform focuses on delivering efficient, guideline-concordant care for managing cardiovascular health, particularly in remote settings. Healthcare providers gain the capability to remotely track and analyze blood pressure and a spectrum of vital cardiovascular indicators through its software. By aligning patient data with clinical best practices, mmHg enhances decision-making precision, driving timely and accurate interventions. North American institutions such as Beth Israel Deaconess (Harvard Medical), Johns Hopkins, Columbia University, NYU, Tulane University, and the University of British Columbia rely on the platform to advance both patient outcomes and clinical research, according to mmHg.

By combining mmHg’s advanced remote monitoring capabilities with Myant’s advanced material and textile computing technology, healthcare providers will have access to continuous, real-time patient data, enabling earlier detection of health risks, personalized treatment plans, and better chronic disease management. The result is early disease detection that improves health outcomes, reduces hospital visits, and enhances the quality of life.

“The combination of Myant’s textile technology and mmHg’s clinically-infused software architecture will no doubt create the next generation of personalized care-delivery, where patients will be able to transmit clinical-grade, continuous vitals data feeds to a platform that presents the data in an efficient and clinically relevant manner to care teams,” mmHg Co-Founder/Chief Operating Officer Peter Wood stated.

The acquisition aligns with Myant’s ongoing efforts to leverage AI and advanced materials to improve patient outcomes and extend human life, and adds new capabilities to Myant’s fully vertical integrated solutions.

Myant is leading an evolution where AI guardians can enhance human capabilities through textile interfaces,  a connected, protective second skin. This second skin—made possible by advanced materials—blends naturally into everyday life, setting a new standard for seamless interaction with the digital world. In 2024, ⁠⁠Myant launched with significant growth into the EU and brought on world renowned AI scientist Dr. Xin Gao as its chief AI officer.

mmHg Inc. is a digital health company that provides remote blood pressure monitoring and cardiovascular risk management solutions. Its products, co-developed by former CEO and Principal Founder Dr. Raj Padwal, are designed to enhance clinical care and are widely used by North American healthcare providers and researchers.